Positiv-inotrope Substanzen in der Kardiologie

  • G. F. Hauf
  • E. Grom
Chapter

Zusammenfassung

Die Reduktion der Vor- und Nachlast bei myokardialer Dysfunktion durch ACE-Inhibitoren, AT1Rezeptor-lnhibitoren und Vasodilatatoren, evtl. ergänzt durch Diuretika, bessert v.a. indirekt die Förderleistung des Herzens. In Abhängigkeit vom Schweregrad der myokardialen Schädigung kann es zusätzlich erforderlich sein, direkt die Inotropie des Herzmuskels zu steigern. Dabei muss unterschieden werden zwischen der Notwendigkeit einer evtl. Akutintervention sowie einer möglichen Langzeittherapie.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amin DK, Shah PK, Hülse S et al (1984) Myocardial metabolit and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. Am Heart J 108:1285PubMedCrossRefGoogle Scholar
  2. Applefeld MM, Newman KA, Grove WR et al (1983) Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 51:455PubMedCrossRefGoogle Scholar
  3. Bairn DS, McDwell AV, Cherniles J et al (1983) Evaluation of a new bipyridine inotropic agent — milrinone — in patients with severe congestive heart failure. New Engl Med 309:748CrossRefGoogle Scholar
  4. Benotti Jr, Grossman W, Braunwald E et al (1978) Hemodynamic assessment of amiodarone. A new inotropic agent. N Engl J Med 299:1373PubMedCrossRefGoogle Scholar
  5. Bloom PhM, Nelp WB (1966) Relationship of the excretion of tritiated digoxin to renal function. Am J med Sci 251:43CrossRefGoogle Scholar
  6. Cohn JN, Goldstein SO, Greenberg BH et al (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339:1810PubMedCrossRefGoogle Scholar
  7. Cyran J, Bolte HD (1979) Kombinierte Infusion von Nitroprussid-Natrium und Dobutamin zur Behandlung der hochgradigen Linksherzinsuffizienz bei koronarer Herzkrankheit. Klin Wochenschr 57:883PubMedCrossRefGoogle Scholar
  8. Cyran J, Kühnl Ch, Zähringer J et al (1978) Die Änderung der Hämodynamik des Herzens unter dem kombinierten Einfluß von Nitroglycerin und Dopamin bei hochgradiger Linksherzinsuffizienz. Z Kardiol 67:759PubMedGoogle Scholar
  9. Delius W, Wirtzfeld A, Sebening H, Mathes P (1976) Hämodynamische Wirkung von Dobutamin bei Patienten mit Herzinsuffizienz. Dtsch med Wschr 101:1747PubMedCrossRefGoogle Scholar
  10. Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525CrossRefGoogle Scholar
  11. Erdmann E, Brown L, Lorenz B et al (1985a) Altersabhängige Regulation der Herzglykosidrezeptoren. Z Kardiol 74(Suppl 7):33PubMedGoogle Scholar
  12. Erdmann E, Werdan K, Brown L (1985b) Multiplicity of cardiac glycoside receptor in the heart. Trends Pharmacol Sci 6:293CrossRefGoogle Scholar
  13. Ferguson DW (1990) Baroreflex-mediated circulatory control in human heart failure. Heart Failure 6:3Google Scholar
  14. Figgitt DP, Gillies PS, Goa KL (2001) Levosimendan. Drugs 61:613PubMedCrossRefGoogle Scholar
  15. Follath F, Cleland JGF, Just H et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO-study): a randomised double-blind trial. Lancet 360:196PubMedCrossRefGoogle Scholar
  16. Goldberg LI, Rajfer SI (1985) Dopamine receptors: applications in clinical cardiology: Circulation 72:245PubMedGoogle Scholar
  17. Grosse-Brockhoff F, Hengels KJ, Fritsch WP et al (1973) Serumdigoxinspiegel und Nierenfunktion. Dtsch med Wochenschr 98:1547PubMedCrossRefGoogle Scholar
  18. Hauf GF, Bubenheimer P, Roskamm H (1981) The acute effect of a new positive inotropic agent (AR-L115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure. Arzneim Forsch 31(la):253Google Scholar
  19. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP for the Milrinone-Dobutamine Study Group (1996) Comparative efficacy of short-term interavenous infusiaon of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Clin Cardiol 19:21Google Scholar
  20. Kereiakes DJ, Viquerat C, Lanzer P et al (1984) Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure.Am Heart J 108:1278PubMedCrossRefGoogle Scholar
  21. Klein G, Sauer E, Bauer R, Wirtzfeld A, Sebening H (1981) The comparison of the effects of AR-L 115 BS and dobutamine in patients with severe cardiac failure. Arzneim Forsch 31(l,la):257Google Scholar
  22. König K, Reindell H, Hoffmann G, Achtermann R (1964) Zur Frage der Glykosid-Therapie bei der latenten Herzinsuffizienz (Belastungsinsuffizienz) unter besonderer Berücksichtigung des Altersherzens. Arch Kreisl Forsch 43:86CrossRefGoogle Scholar
  23. Kubo SH, Cody RJ, Chatterjee K et al (1985) Acute dose range study of milrinone in congestive heart failure. Am J Cardiol 55:726PubMedCrossRefGoogle Scholar
  24. Kubo SH, Gollub S, Bourge R et al (1992) Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 85:942PubMedCrossRefGoogle Scholar
  25. Leier CV, Huss P, Lewis RP, Unverferth DV (1982) Drug-induced conditioning in congestive heart failure. Circulation 65:1382PubMedCrossRefGoogle Scholar
  26. Liang CS, Sherman LG, Doherty JU et al (1984) Sustained improvement of cardiac function in patients with congestive heart failure after shortterm infusion of dobutamine. Circulation 69:113PubMedCrossRefGoogle Scholar
  27. Mager G, Klocke RK, Kux A, Höpp HW, Hilger HH (1990) Therapie des kardiogenen Schocks und der schwersten Herzinsuffizienz mit dem Phosphodiesterasehemmer Milrinon. Intensivmed 27:238Google Scholar
  28. Mason DT, Spann Jr JF, Zelis R (1969) New developments in the understanding of the actions of the digitalis glycosides. Progr cardiovasc Dis 11:443CrossRefGoogle Scholar
  29. Murphy MB, Murray C, Shorten GD (2001) Fenoldopam — a selective peripheral dopamine receptor agonist for the treatment of severe hypertension. N Eng J Med 346:1548Google Scholar
  30. Ooi H, Colucci WS (2001) Pharmacological treatment of heart failure. In: Gooman and Gilman’s The pharmacological basis of therapeutics, 10th ed. McGraw-Hill New York, p 901Google Scholar
  31. Packer M, Medina N, Yushak M (1984) Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70:1038PubMedCrossRefGoogle Scholar
  32. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403PubMedCrossRefGoogle Scholar
  33. Rüegg J C (1986) Effects of new inotropic agents on Ca++ sensitivity of contractile proteins. Circulation 73(Suppl lll):78Google Scholar
  34. Scholz H, Meyer W (1986) Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation 73(Suppl lll):99Google Scholar
  35. Shah PK, Amin DK, Hulse S et al (1985) Inotropic therapy for refractory congestive heart failure with oral enoximone (MDL-17,043); poor long-term results despite early hemodynamic and clinical improvement. Circulation 71:326PubMedCrossRefGoogle Scholar
  36. Simoons ML, Muskens G, Hugenholtz PG (1983) Hemody namic effects of salmazol (ARL-115 BS), a new vasodilator and positive inotropic agent, in patients with cardiogenic shock. Herz 8:34PubMedGoogle Scholar
  37. Skou JC (1957) The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochem Biophys Acta 23:349CrossRefGoogle Scholar
  38. Solaro RJ, Rüegg JC (1982) Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115 BS, a novel cardiotonic agent. Circulat Res 51:290PubMedCrossRefGoogle Scholar
  39. Sonnenblick EH, Frishman WH, LeJemtel TH (1979) Dobutamine: A new synthetic cardioactive sympathetic amine. New Engl J Med 300:17PubMedCrossRefGoogle Scholar
  40. Storstein O, Hansteen V, Hatle L et al (1977) Studies on digitalis XIII. A prospective study of 649 patients on maintenance treatment with digitoxin. Am Heart J 93:434PubMedCrossRefGoogle Scholar
  41. Toda N, West CT (1969) The action of ouabain on cholinergic responses in the sinoatrial mode. J Pharmacol Exp Ther 153:774Google Scholar
  42. Tuttle RR (1978) ß-selectivity of dobutamine and its potential für cardiovascular therapy. In: Just H (Hrsg) Dobutamin. Springer, Berlin Heidelberg New York, S 61CrossRefGoogle Scholar
  43. Tuttle RR, Mills J (1975) Dobutamine. Development of a new catecholamine to selectively increase cardiac contractility. Circulat Res 36:185PubMedCrossRefGoogle Scholar
  44. Uretsky BF, Jessup M, Konstam MA et al (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82:774PubMedCrossRefGoogle Scholar
  45. Werdan K, Erdmann E (1988) Glykosidrezeptoren des Herzens. Fortschr Med 106:135PubMedGoogle Scholar
  46. Wirtzfeld A, Klein G, Delius W et al (1978) Dopamin und Dobutamin in der Behandlung der schweren Herzinsuffizienz. Dtsch med Wschr 103:1915PubMedCrossRefGoogle Scholar
  47. Withering W (1937) An account of the foxglove and some of its medical uses: With practical remarks on dropsy and other diseases. C.G.J.&J. Robinson, London 1785, reprinted in Med Class 2:305Google Scholar
  48. Yasunari K, Kohno M, Kano H et al (2000) Dopamine as a novel antooxidative agent for rat vascular smooth muscle cells through dopamine D1-like receptors. Circulation 101:2302PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • G. F. Hauf
  • E. Grom

There are no affiliations available

Personalised recommendations